Further Information
AKAP9, CG-NAP, PRKA9, YOTIAO, AKAP350, HYPERION, KIAA0803, A kinase (PRKA) anchor protein (yotiao) 9, AKAP120-like protein, kinase N-associated protein, A-kinase anchoring protein 450, A-kinase anchor protein, 350kDa, protein kinase A anchoring protein 9, centrosome- and golgi-localized protein, AKAP450, MU-RMS-40.16A, A-kinase anchor protein 9, AKAP9-BRAF fusion protein
Peptide ELISA: antibody detection limit dilution 1:64000.Western Blot:This product has been successfully used by a customer, showing a band at approx 450kDa in lysates of cell line HepG2 (calculated MW of 453kDa according to NP_005742.4). Recommended concentration: 1-3ug/ml.Immunofluorescence: Strong expression of the protein seen in the cytoplasm of A431 and U2OS cells. Recommended concentration: 10ug/ml.
- Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, Rabes HM, Fagin JA, Nikiforov YE. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest. 2005 Jan;115(1):94-101.
Supplied at 0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin.
Aliquot and store at -20?C. Minimize freezing and thawing.
500 ug/mL
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Expected Species Reactivity based on sequence homology: Mouse
The immunogen for this antibody is: C-SGSTTQFHAGMR
10142
A kinase (PRKA) anchor protein 9
AKAP9
Homo sapiens
Liquid
NP_005742.4, NP_671714.1
22538391
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
Cancer
This antibody is expected to recognise isoforms 2 and 3 (NP_005742.4; NP_671714.1 respectively). The isoforms Yotiao, AKAP350B and AKAP350C are not recognized.
Q99996